
Reporting Period: April 1–7, 2026
The AeroClenz Chief Medical Officer periodically reviews publicly available infectious disease surveillance reports from organizations such as the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and European Centre for Disease Prevention and Control (ECDC).
These summaries are intended to provide general awareness of global infectious disease activity relevant to international travel, healthcare systems, and high-traffic indoor environments.
This information is provided for situational awareness only and does not constitute medical advice.
Key Takeaways
For the period of April 1–7, 2026, several notable global infectious disease trends were observed:
• Measles continues to present a significant disruption risk due to high transmissibility and ongoing global outbreaks
• Seasonal respiratory viruses are declining but remain present across multiple regions
• Cholera activity persists in multiple countries, particularly in infrastructure-limited settings
• Chikungunya remains a relevant travel-associated risk in the western Indian Ocean region
• High-consequence pathogens remain contained but continue to be monitored
Top 5 Signals
1) Measles remains the highest disruption risk per case
CDC’s most recent update reports 1,487 confirmed measles cases in the United States as of March 19, 2026, with approximately 94% associated with outbreaks.
Global surveillance continues to indicate measles activity across multiple regions, reinforcing its role as a highly transmissible disease with the potential for rapid spread through travel networks.
2) Respiratory virus season is declining, but not over
WHO reports that by week 12:
• Global influenza positivity has fallen below 10%
• SARS-CoV-2 activity remains low
• RSV activity remains stable at low levels
These trends indicate improving conditions, though respiratory viruses remain present.
3) Cholera remains a significant global concern
WHO continues to report multi-country cholera activity, with 18,715 cases and 269 deaths recorded in February 2026, representing an increase in mortality compared to January.
Cholera risk remains closely associated with water, sanitation, and healthcare infrastructure conditions.
4) Chikungunya remains a travel-associated risk
Chikungunya transmission in the Seychelles continues to be monitored by public-health agencies.
CDC maintains a Level 2 travel notice, and ECDC has previously documented increases in travel-associated cases linked to the region.
5) High-consequence zoonotic threats remain contained
WHO continues to assess recent Nipah virus events in India and Bangladesh as low risk at regional and global levels.
Ebola and Marburg outbreaks previously reported in the Democratic Republic of Congo and Ethiopia, respectively, remain in post-outbreak status.
Global Situation Overview
Respiratory Viruses
The global respiratory disease picture continues to improve.
WHO’s most recent update indicates:
• Declining influenza detections globally
• Influenza positivity below 10%
• Low SARS-CoV-2 activity
• Stable, low RSV activity
As the season progresses, influenza B is accounting for a larger share of detections.
Measles
Measles remains one of the most impactful infectious diseases in this update due to:
• High transmissibility
• Amplification through international travel
• Resource-intensive contact tracing
CDC data confirms continued outbreak activity in 2026, alongside ongoing global transmission.
Air Travel and Measles Exposure
Public-health guidance continues to emphasize that measles cases associated with air travel can result in extensive contact investigations.
Guidance also highlights the importance of recognizing potential symptoms during travel and ensuring timely communication with public-health authorities when cases are suspected.
Cholera
Cholera continues to be reported across multiple regions, particularly in areas where water and sanitation infrastructure is limited.
Recent updates indicate a notable increase in deaths relative to case counts, suggesting continued severity in affected areas.
Mpox
Mpox continues to be monitored globally, with ongoing reporting of clade Ib-associated activity and continued transmission in certain regions.
While not the dominant signal during this reporting period, it remains a relevant public-health consideration.
Arboviruses: Chikungunya and Dengue
Chikungunya activity in the Seychelles remains a relevant travel-associated signal.
Public-health agencies continue to emphasize mosquito precautions and awareness for travelers to affected regions.
Dengue remains a significant global burden, particularly in the Americas, though recent data suggests lower activity compared to the same period in 2025.
High-Consequence Pathogens
Nipah virus:
Recent events remain limited, with no evidence of sustained transmission.
Ebola and Marburg viruses:
No active outbreaks are currently reported. Previous outbreaks have been declared contained following appropriate monitoring periods.
These pathogens continue to be monitored due to their potential severity despite low current transmission risk.
Summary
The global infectious disease landscape for early April 2026 reflects improving respiratory virus trends alongside continued monitoring of high-impact and travel-associated risks.
Key themes include:
• Measles as the most significant disruption risk per individual case
• Declining but ongoing respiratory virus activity
• Persistent cholera transmission in infrastructure-limited settings
• Continued relevance of chikungunya as a travel-associated risk
• Contained but closely monitored high-consequence pathogens
Public-health surveillance agencies continue to monitor these developments and publish updates as new information becomes available.
Sources referenced in this summary include the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the European Centre for Disease Prevention and Control (ECDC), and peer-reviewed literature, including the Journal of Travel Medicine.
To learn more about AeroClenz, visit www.aeroclenz.com. Follow AeroClenz on social media for updates on research and technology developments.
LinkedIn: https://www.linkedin.com/company/aeroclenz
Facebook: https://www.facebook.com/AeroClenz
Instagram: https://www.instagram.com/aeroclenz_